Novartis, MMV announce decision to move to phase 3 study for novel ganaplacide/lumefantrine─SDF combination in adults and children with malaria

… Plasmodium falciparum. Ganaplacide is a novel agent with a new mechanism … non-artemisinin-based medicines with novel mechanisms of action against resistant … for Malaria Venture (MMV) and Singapore Economic Development Board supported joint …